[go: up one dir, main page]

MA28084A1 - Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione - Google Patents

Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione

Info

Publication number
MA28084A1
MA28084A1 MA28911A MA28911A MA28084A1 MA 28084 A1 MA28084 A1 MA 28084A1 MA 28911 A MA28911 A MA 28911A MA 28911 A MA28911 A MA 28911A MA 28084 A1 MA28084 A1 MA 28084A1
Authority
MA
Morocco
Prior art keywords
polymorphic forms
isoindol
dione
piperidine
dihydro
Prior art date
Application number
MA28911A
Other languages
English (en)
Inventor
Roger Shen-Chu Chen
George W Muller
Markian S Jaworsky
Manohar T Saindane
Louise M Cameron
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MA28084A1 publication Critical patent/MA28084A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2857—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it
    • B65D51/2864—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it the element being a plug or like element closing a passage between the auxiliary container and the main container
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

L¿invention concerne des formes polymorphes de 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-pipéridine-2-6-dione. L¿invention concerne aussi des compositions comportant ces formes polymorphes, des procédés pour la production desdites formes polymorphes et des procédés pour leur utilisation.
MA28911A 2003-09-04 2006-04-03 Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione MA28084A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49972303P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
MA28084A1 true MA28084A1 (fr) 2006-08-01

Family

ID=34272860

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28911A MA28084A1 (fr) 2003-09-04 2006-04-03 Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione

Country Status (37)

Country Link
US (20) US7465800B2 (fr)
EP (7) EP2425836A1 (fr)
JP (6) JP4733037B2 (fr)
KR (3) KR101005991B1 (fr)
CN (7) CN104059052A (fr)
AP (1) AP2324A (fr)
AR (2) AR047994A1 (fr)
AT (1) ATE531369T1 (fr)
AU (2) AU2004270211B2 (fr)
BR (1) BRPI0414084A (fr)
CA (9) CA2688708C (fr)
CR (2) CR8291A (fr)
CY (1) CY1112017T1 (fr)
DK (5) DK3042659T3 (fr)
EA (1) EA009922B1 (fr)
EC (1) ECSP066467A (fr)
ES (5) ES2402808T3 (fr)
GE (1) GEP20104958B (fr)
HK (1) HK1202531A1 (fr)
HR (1) HRP20110836T1 (fr)
HU (3) HUE041265T2 (fr)
IL (5) IL174067A (fr)
IS (1) IS8340A (fr)
MA (1) MA28084A1 (fr)
ME (3) ME01530B (fr)
MX (6) MX346372B (fr)
NO (4) NO336898B1 (fr)
NZ (1) NZ546054A (fr)
OA (1) OA13250A (fr)
PE (1) PE20060284A1 (fr)
PL (5) PL3042659T3 (fr)
PT (5) PT3042659T (fr)
RS (3) RS20120339A1 (fr)
SI (2) SI1667682T1 (fr)
UA (1) UA83504C2 (fr)
WO (1) WO2005023192A2 (fr)
ZA (1) ZA200601858B (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
NZ526683A (en) * 2000-11-30 2008-03-28 Childrens Medical Center Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP1755600A2 (fr) * 2004-04-23 2007-02-28 Celgene Corporation Procedes d'utilisation et compositions comportant des composes immunomodulateurs pour le traitement et le controle de l'hypertension pulmonaire
AU2006265601A1 (en) * 2005-06-30 2007-01-11 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
CA2612612C (fr) * 2005-06-30 2014-03-11 Celgene Corporation Elaboration de composes 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dioniques
EP1919500A2 (fr) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Traitement d'ulceres de la jambe a l'aide d'un tissu biologique a base de collagene derive de placenta
EP1919365A2 (fr) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Obturateur oculaire forme a partir dun tissu biologique a base de collagene derive du placenta
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007136640A2 (fr) * 2006-05-16 2007-11-29 Celgene Corporation Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
WO2008021391A1 (fr) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Biomatériau à base de cordon ombilical pour usage médical
WO2008042441A1 (fr) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Utilisation de biomatériau de cordon ombilical en chirurgie oculaire
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
KR20220109484A (ko) 2006-10-06 2022-08-04 안트로제네시스 코포레이션 천연(텔로펩티드) 태반 콜라겐 조성물
NZ584458A (en) 2007-09-28 2012-09-28 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2235213A2 (fr) 2007-12-20 2010-10-06 Celgene Corporation Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
EP2262768A4 (fr) * 2008-03-11 2011-03-23 Reddys Lab Ltd Dr Préparation de lénalidomide
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
CN102272118A (zh) * 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
EP2355802A1 (fr) * 2008-11-14 2011-08-17 Ratiopharm GmbH Produits intermédiaires et formes galéniques orales contenant de la lénalidomide
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
EP2350055A4 (fr) * 2008-11-17 2012-04-18 Reddys Lab Ltd Dr Solvates de lénalidomide et procédés correspondants
WO2010065939A1 (fr) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
SI2403845T1 (sl) 2009-03-02 2014-09-30 Generics (Uk) Limited Izboljšani postopek
WO2010129636A2 (fr) * 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lénalidomide polymorphe
UA102582C2 (en) 2009-05-19 2013-07-25 Селджин Корпорейшн Oral dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CN101665484B (zh) * 2009-07-20 2012-11-21 上海皓元生物医药科技有限公司 一种制备来那度胺的方法
EA201270261A1 (ru) 2009-08-12 2012-07-30 Синтон Б. В. Соли леналидомида
PL2477973T3 (pl) 2009-09-16 2015-04-30 Ranbaxy Laboratories Ltd Sposób wytwarzania krystalicznej formy lenalidomidu
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (fr) 2009-10-29 2011-05-05 Ratiopharm Gmbh Sels d'addition d'acide du lénalidomide
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (fr) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Procédé pour la préparation de forme b de lénalidomide
WO2011069608A1 (fr) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lénalidomide, ses formes polymorphes et mélange comprenant du s- et r-lénalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
JP2013519675A (ja) 2010-02-11 2013-05-30 セルジーン コーポレイション アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法
WO2011111053A1 (fr) 2010-03-08 2011-09-15 Natco Pharma Limited Forme i de lénalidomide anhydre
WO2011160042A2 (fr) 2010-06-18 2011-12-22 Makoto Life Sciences, Inc. Modulateurs de prpk-tprkb et leurs utilisations
US9918197B2 (en) 2010-10-04 2018-03-13 Lazo Inc. Interactive advertisement environment
WO2012078492A1 (fr) 2010-12-06 2012-06-14 Celgene Corporation Traitement d'association avec du lénalidomide et un inhibiteur de cdk pour traiter le myélome multiple
CN102070606A (zh) * 2011-02-17 2011-05-25 江苏先声药物研究有限公司 一种雷利度胺a晶型新的制备方法
CN102643266B (zh) * 2011-02-17 2015-02-18 江苏先声药物研究有限公司 一种雷利度胺b晶型的制备方法
AU2012229279B2 (en) 2011-03-11 2017-06-22 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP2688649B1 (fr) * 2011-03-23 2019-04-10 Hetero Research Foundation Forme polymorphe de lénalidomide
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
WO2013005229A1 (fr) * 2011-07-05 2013-01-10 Hetero Research Foundation Procédé de préparation de lénalidomide
JP2015534989A (ja) * 2012-10-22 2015-12-07 コンサート ファーマシューティカルズ インコーポレイテッド ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
WO2014110558A1 (fr) 2013-01-14 2014-07-17 Deuterx, Llc Dérivés de 3-(5-substituté-4-oxoquinazolin-3(4h)-yl)-3-deutéro-pipéridine-2,6-dione
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
AU2014236597A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
CN104072476B (zh) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 泊马度胺晶型及其制备方法和用途
WO2014170909A2 (fr) * 2013-04-01 2014-10-23 Hetero Research Foundation Procédé de préparation de pomalidomide
AU2014315415A1 (en) * 2013-09-03 2016-03-10 Fugro Chance, Inc. Interactive remote guidance system for seaborne vessels
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
EP2875817B1 (fr) * 2013-11-26 2020-03-18 Synhton B.V. Formulation pharmaceutique comprenant du lénalidomide amorphe
AU2015210999A1 (en) 2014-01-29 2016-07-21 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
WO2015113314A1 (fr) * 2014-01-30 2015-08-06 上海创诺制药有限公司 Nouvelle forme cristalline de 3- (4-amino -1,3-dihydro -1-oxo -2 h-isoindole -2-yl) -2,6-pipéridinedione et procédé de préparation correspondant
CN104016966A (zh) * 2014-01-30 2014-09-03 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
BR112016024510A2 (pt) * 2014-04-22 2017-08-15 H Lundbeck As ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
CN105085473B (zh) * 2014-04-24 2019-06-18 江苏豪森药业集团有限公司 来那度胺晶型及其制备方法和医药用途
WO2014155371A2 (fr) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Procédé de préparation de lénalidomide cristallin
US20150348512A1 (en) * 2014-06-01 2015-12-03 Apple Inc. Method and apparatus for representing a device's traversal along a route
US10392364B2 (en) 2014-08-11 2019-08-27 Avra Laboratories Pvt. Ltd. Process for synthesis of lenalidomide
EA201790439A1 (ru) 2014-08-22 2017-07-31 Селджин Корпорейшн Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
US9794331B1 (en) * 2014-09-29 2017-10-17 Amazon Technologies, Inc. Block allocation based on server utilization
US10471156B2 (en) 2014-12-19 2019-11-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
US10507204B2 (en) 2014-12-19 2019-12-17 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
CN104610210B (zh) * 2015-02-05 2017-06-16 天津大学 一种脱氢醋酸钠无水物制备方法
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
LT3135275T (lt) 2015-08-27 2020-09-25 Grindeks, A Joint Stock Company Farmacinė kompozicija, gebanti įtraukti įvairių kristalinių modifikacijų lenalidomidą
EP3393457A1 (fr) 2015-12-22 2018-10-31 Synthon B.V. Composition pharmaceutique comprenant du lénalidomide amorphe et un antioxydant
RU2616976C1 (ru) * 2016-04-07 2017-04-19 Олег Ростиславович Михайлов Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе
WO2018013693A1 (fr) 2016-07-13 2018-01-18 Celgene Corporation Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser
TWI664172B (zh) * 2016-08-25 2019-07-01 大陸商浙江海正藥業股份有限公司 來那度胺的晶型及其製備方法和用途
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN108658935A (zh) * 2017-03-27 2018-10-16 天津大学 来那度胺新晶型、其制备方法及其医药用途
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
CN112062751A (zh) * 2017-08-04 2020-12-11 正大天晴药业集团股份有限公司 一种来那度胺的新结晶及其药物组合物
CN111107874A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
WO2019067792A1 (fr) 2017-09-28 2019-04-04 Celularity, Inc. Suppression de tumeur à l'aide de cellules tueuses naturelles intermédiaires dérivées du placenta humain (pink) en combinaison avec un anticorps
CA3079567A1 (fr) 2017-10-26 2019-05-02 Synbias Pharma Ag Formulations a liberation immediate de lenalidomide
EP3505158A1 (fr) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Composition pharmaceutiquie comprenant des sels d'addition d'acide du lénalidomide
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
CA3087565A1 (fr) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Inhibiteurs selectifs d'histone deacetylase pour le traitement d'une maladie humaine
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
CN108840908A (zh) * 2018-07-10 2018-11-20 刘凤娟 特拉匹韦的一种新晶型及其制备方法
CN111217792B (zh) * 2018-11-23 2021-09-28 欣凯医药化工中间体（上海）有限公司 一种来那度胺b晶型的制备方法
WO2022150561A1 (fr) 2021-01-08 2022-07-14 Starton Therapeutics, Inc. Solutions stables de composés imides immunomodulateurs pour une utilisation parentérale
WO2023126530A1 (fr) 2021-12-31 2023-07-06 A Fine House S.A. Solution orale comprenant du lénalidomide
US20250170115A1 (en) 2021-12-31 2025-05-29 A Fine House S.A. Lenalidomide oral solution

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992014455A1 (fr) 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU690377B2 (en) * 1994-11-04 1998-04-23 Polymun Scientific Immunobiologische Forschung Gmbh Application of superoxide dismutase in liposomes
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
CA2560523C (fr) * 1996-07-24 2011-09-20 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)-phtalimides et 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substitues et methode pour reduire les niveaux de tnf.alpha
KR100539031B1 (ko) 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를감소시키는 방법
EP1920773B1 (fr) 1996-11-05 2011-01-05 The Children's Medical Center Corporation Thalidomide et dexamethasone pour le traitement des tumeurs
WO1998035021A1 (fr) 1997-02-05 1998-08-13 University Of Hertfordshire Preparation de spheroides et utilisation de ces derniers pour des applications therapeutiques ou diagnostiques
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
KR20060036124A (ko) 1998-03-16 2006-04-27 셀진 코포레이션 염증성 사이토카인 억제제용2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그제조방법 및 그 용도
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
CZ20013338A3 (cs) 1999-03-18 2002-03-13 Celgene Corporation Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CA2319872C (fr) 2000-02-02 2012-06-19 Chun-Ying Huang Composition pharmaceutique pour le traitement du carcinome hepatocellulaire
JP2003527443A (ja) 2000-03-17 2003-09-16 セル・セラピューティックス・インコーポレーテッド ポリグルタミン酸−カンプトセシン結合体およびその調製方法
CN1420776A (zh) 2000-03-31 2003-05-28 塞尔基因公司 环氧合酶－2活性的抑制
JP5409981B2 (ja) 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法
WO2002026737A1 (fr) * 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
NZ526683A (en) 2000-11-30 2008-03-28 Childrens Medical Center Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
PT1423115E (pt) 2001-08-06 2009-07-21 Childrens Medical Center Actividade antiangiogénica de análogos da talidomida substituídos com nitrogénio
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
JP2005536189A (ja) 2002-04-12 2005-12-02 セルジーン・コーポレーション 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
NZ584663A (en) 2002-05-17 2011-09-30 Celgene Corp Use of immunomodulatory amino-dione derivatives for treating leukemia
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1675857B1 (fr) * 2003-10-22 2011-07-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Derives de pyrrolobenzodiazepine, compositions comprenant ces derives et methodes s'y rapportant
ZA200702382B (en) 2004-09-03 2008-08-27 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
WO2007136640A2 (fr) 2006-05-16 2007-11-29 Celgene Corporation Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
US20090092343A1 (en) * 2007-10-05 2009-04-09 Mary Thomson Locking Bag with Locking Handle
EP2262768A4 (fr) * 2008-03-11 2011-03-23 Reddys Lab Ltd Dr Préparation de lénalidomide
CN101531653B (zh) 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
US8071638B2 (en) 2008-08-14 2011-12-06 Teva Pharmaceutical Industries Ltd. Solid states of atorvastatin potassium
CN102272118A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
EP2355802A1 (fr) 2008-11-14 2011-08-17 Ratiopharm GmbH Produits intermédiaires et formes galéniques orales contenant de la lénalidomide
EP2350055A4 (fr) 2008-11-17 2012-04-18 Reddys Lab Ltd Dr Solvates de lénalidomide et procédés correspondants
SI2403845T1 (sl) 2009-03-02 2014-09-30 Generics (Uk) Limited Izboljšani postopek
WO2010129636A2 (fr) 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lénalidomide polymorphe
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
EA201270261A1 (ru) 2009-08-12 2012-07-30 Синтон Б. В. Соли леналидомида
WO2011027326A1 (fr) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Procédé de préparation de lénalidomide
PL2477973T3 (pl) 2009-09-16 2015-04-30 Ranbaxy Laboratories Ltd Sposób wytwarzania krystalicznej formy lenalidomidu
TWI475014B (zh) 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (fr) 2009-10-29 2011-05-05 Ratiopharm Gmbh Sels d'addition d'acide du lénalidomide
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (fr) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Procédé pour la préparation de forme b de lénalidomide
WO2011064574A1 (fr) 2009-11-24 2011-06-03 Generics [Uk] Limited Procédés de hplc permettant la détection de la lénalidomide
WO2011069608A1 (fr) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lénalidomide, ses formes polymorphes et mélange comprenant du s- et r-lénalidomide
CN101817813B (zh) 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
WO2011111053A1 (fr) 2010-03-08 2011-09-15 Natco Pharma Limited Forme i de lénalidomide anhydre
CN101791288B (zh) 2010-04-07 2011-12-28 南京卡文迪许生物工程技术有限公司 一种稳定的来那度胺口服固体制剂
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法

Also Published As

Publication number Publication date
EP3045176B8 (fr) 2018-12-12
SI1667682T1 (sl) 2011-12-30
US20160009684A1 (en) 2016-01-14
HK1148974A1 (en) 2011-09-23
ES2718925T3 (es) 2019-07-05
AU2009200257B2 (en) 2012-02-02
CN102060843A (zh) 2011-05-18
US20180072700A1 (en) 2018-03-15
MX342025B (es) 2016-09-12
CN102060843B (zh) 2013-08-14
US8143286B2 (en) 2012-03-27
EP3042659B1 (fr) 2018-11-07
US20220127244A1 (en) 2022-04-28
ECSP066467A (es) 2006-09-18
ES2718926T3 (es) 2019-07-05
US7465800B2 (en) 2008-12-16
NO20150253L (no) 2006-06-02
US20090149499A1 (en) 2009-06-11
PT2426118E (pt) 2013-04-04
KR100979869B1 (ko) 2010-09-02
KR101005991B1 (ko) 2011-01-05
ME01572B (me) 2014-09-20
JP2014094957A (ja) 2014-05-22
WO2005023192A3 (fr) 2005-09-29
ZA200601858B (en) 2007-07-25
EP3042659B8 (fr) 2018-12-19
CN1871003B (zh) 2012-03-14
AP2324A (en) 2011-11-21
IL174067A0 (en) 2006-08-01
US8058443B2 (en) 2011-11-15
CN101838261A (zh) 2010-09-22
CA2537092C (fr) 2011-08-09
RS20120340A1 (sr) 2013-04-30
US7977357B2 (en) 2011-07-12
US9353080B2 (en) 2016-05-31
IL225792A0 (en) 2013-06-27
IL174067A (en) 2015-07-30
ME01571B (fr) 2014-09-20
HUE041265T2 (hu) 2019-05-28
EP3045176A1 (fr) 2016-07-20
NO20061528L (no) 2006-06-02
OA13250A (en) 2007-01-31
CA2741412A1 (fr) 2005-03-17
CN101863878B (zh) 2012-07-18
JP4733037B2 (ja) 2011-07-27
CN101838261B (zh) 2013-07-10
NO20160131A1 (no) 2016-01-28
CN102675281B (zh) 2016-01-20
HRP20110836T1 (hr) 2011-12-31
JP2011006470A (ja) 2011-01-13
US20090187023A1 (en) 2009-07-23
WO2005023192A2 (fr) 2005-03-17
ME01530B (me) 2011-10-10
AU2004270211B2 (en) 2008-10-23
PL3045175T3 (pl) 2019-04-30
CA2688708A1 (fr) 2005-03-17
MX342071B (es) 2016-09-13
AP2006003558A0 (en) 2006-04-30
CN101863878A (zh) 2010-10-20
PL3045176T3 (pl) 2019-04-30
NO341035B1 (no) 2017-08-07
CA2741412C (fr) 2013-07-16
JP5925418B2 (ja) 2016-05-25
PT3042659T (pt) 2019-02-04
EP3045175B8 (fr) 2018-12-19
CA2687927A1 (fr) 2005-03-17
CA2537092A1 (fr) 2005-03-17
MX346372B (es) 2017-03-16
US20090062343A1 (en) 2009-03-05
AR047994A1 (es) 2006-03-15
US20170121305A1 (en) 2017-05-04
EP3045175B1 (fr) 2018-11-07
US8431598B2 (en) 2013-04-30
SI2426118T1 (sl) 2013-06-28
US20120029020A1 (en) 2012-02-02
NO341039B1 (no) 2017-08-14
EP3042659A1 (fr) 2016-07-13
DK2426118T3 (da) 2013-03-25
US9365538B2 (en) 2016-06-14
PL1667682T3 (pl) 2012-04-30
CY1112017T1 (el) 2015-11-04
US20120046316A1 (en) 2012-02-23
CN104059052A (zh) 2014-09-24
US20120029019A1 (en) 2012-02-02
NZ546054A (en) 2009-12-24
PT3045175T (pt) 2019-02-04
RS20060158A (sr) 2008-08-07
US20120022106A1 (en) 2012-01-26
EP1667682A2 (fr) 2006-06-14
DK3045176T3 (en) 2019-02-25
US11655232B2 (en) 2023-05-23
US20110288127A1 (en) 2011-11-24
PL3042659T3 (pl) 2019-04-30
EA009922B1 (ru) 2008-04-28
EP1667682A4 (fr) 2009-05-06
ES2718927T3 (es) 2019-07-05
HK1157772A1 (en) 2012-07-06
GEP20104958B (en) 2010-04-26
EP3459544A1 (fr) 2019-03-27
US20190218201A1 (en) 2019-07-18
US20200239431A1 (en) 2020-07-30
HK1167646A1 (en) 2012-12-07
EP3045176B1 (fr) 2018-11-07
EP2426118B1 (fr) 2013-01-23
CR8291A (es) 2007-09-17
EP3045175A1 (fr) 2016-07-20
EP1667682B1 (fr) 2011-11-02
HUE041282T2 (hu) 2019-05-28
CN1871003A (zh) 2006-11-29
HK1148274A1 (en) 2011-09-02
CA2688708C (fr) 2011-08-09
HK1202531A1 (en) 2015-10-02
AR102756A2 (es) 2017-03-22
US9371309B2 (en) 2016-06-21
ES2376879T3 (es) 2012-03-20
KR20090086647A (ko) 2009-08-13
DK1667682T3 (da) 2011-12-12
US10590104B2 (en) 2020-03-17
AU2009200257A1 (en) 2009-02-19
IL238911A0 (en) 2015-06-30
KR20080063862A (ko) 2008-07-07
CA2687924A1 (fr) 2005-03-17
US20090149500A1 (en) 2009-06-11
CA2688694C (fr) 2011-08-09
RS53104B (sr) 2014-06-30
NO20161012A1 (no) 2016-06-15
US7855217B2 (en) 2010-12-21
IS8340A (is) 2006-03-07
CA2688709C (fr) 2011-08-09
US8193219B2 (en) 2012-06-05
DK3045175T3 (en) 2019-03-04
MX346261B (es) 2017-03-13
EA200600535A1 (ru) 2006-08-25
JP2011137024A (ja) 2011-07-14
PT3045176T (pt) 2019-02-04
HK1092388A1 (en) 2007-02-09
RS20120339A1 (sr) 2013-04-30
CA2688695C (fr) 2011-08-09
EP2426118A1 (fr) 2012-03-07
US20170121303A1 (en) 2017-05-04
IL207458A0 (en) 2010-12-30
PL2426118T3 (pl) 2013-08-30
CA2688694A1 (fr) 2005-03-17
CN102675281A (zh) 2012-09-19
HUE042071T2 (hu) 2019-06-28
JP5309104B2 (ja) 2013-10-09
CA2688695A1 (fr) 2005-03-17
MXPA06001994A (es) 2006-05-31
US20050096351A1 (en) 2005-05-05
CA2687924C (fr) 2011-08-09
ES2402808T3 (es) 2013-05-09
JP2016074734A (ja) 2016-05-12
CR10967A (es) 2009-12-10
DK3042659T3 (en) 2019-02-25
JP6200977B2 (ja) 2017-09-20
KR20060087543A (ko) 2006-08-02
JP2007504248A (ja) 2007-03-01
CA2741575A1 (fr) 2005-03-17
PT1667682E (pt) 2012-01-19
CN102584788A (zh) 2012-07-18
BRPI0414084A (pt) 2006-10-24
NO337446B1 (no) 2016-04-11
JP2013209407A (ja) 2013-10-10
UA83504C2 (en) 2008-07-25
US20110015228A1 (en) 2011-01-20
ATE531369T1 (de) 2011-11-15
PE20060284A1 (es) 2006-04-13
IL207458A (en) 2015-08-31
IL225791A0 (en) 2013-06-27
CA2741575C (fr) 2013-07-16
US20170121304A1 (en) 2017-05-04
MX346260B (es) 2017-03-13
US8822499B2 (en) 2014-09-02
NO336898B1 (no) 2015-11-23
CA2687927C (fr) 2012-05-29
AU2004270211A1 (en) 2005-03-17
US20090176832A1 (en) 2009-07-09
CA2688709A1 (fr) 2005-03-17
EP2425836A1 (fr) 2012-03-07
US11136306B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
MA28084A1 (fr) Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
MA28329A1 (fr) Formes cristallines de {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]pyridin -3-yl}-(2-chlorophenyl)-methanone.
EP2332932A4 (fr) Nouvelles formes cristallines de 4-(2-aminopyridin-4-yl)-3-(4 fluoro- phényl)-1-(1,4,5,6-tétrahydro-6-oxopyridazin-3-yl)-1h-pyrazole-méthanesulfonate et procédé pour la production de celles-ci
DK1692105T3 (da) Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater
SG121993A1 (en) Process for influencing the properties of combustion residue
TW200732319A (en) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
CY1113926T1 (el) Μεθοδος κατασκευης πολυμορφικων μορφων 3-(4-αμινο-1-οξο-1,3-διϋδρο-ισοϊνδολ-2-υλ)-πιπεριδινο-2,6-διονης
AU2013203194B9 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2004067093A3 (fr) Utilisation de composes chimiques pour le traitement de dyspepsie fonctionnelle